Omnicell, Inc. (NASDAQ: OMCL) develops healthcare technology for autonomous medication management across pharmacy and nursing care settings. Its updates cover financial results, product bookings, recurring revenue, connected-device demand, and product launches such as Omnicell Titan XT and the OmniSphere platform.
Company news also includes healthcare conference presentations, customer engagement programs, clinical leadership roles, and innovation updates tied to automation, AI-enabled intelligence, software workflows, data analytics, and expert services for medication management in healthcare facilities.
Omnicell, Inc. (Nasdaq:OMCL) announced its Summer 2021 Release, enhancing its medication management solutions to improve efficiency, expand automation, and provide better intelligence for healthcare workflows. Key features include improved operating room workflows, decentralized IV compounding, enhanced controlled substance management, and advanced inventory optimization through Omnicell One. This release aims to help healthcare partners maximize technology investments and leverage cloud technology for better scalability. The effort aligns with Omnicell's goal of progressing towards an Autonomous Pharmacy.
Omnicell, Inc. (Nasdaq: OMCL) has announced a partnership with Spartanburg Regional Healthcare System to implement its medication management platform, aiming for enhanced efficiency and safety. The collaboration includes Omnicell’s Central Pharmacy Dispensing and IV Compounding Services, powered by the Omnicell One™ cloud-based intelligence service. This technology aims to improve inventory visibility and reduce medication errors, waste, and costs. Spartanburg Regional is part of nearly 50% of the Top 300 U.S. health systems that are working with Omnicell towards achieving a fully autonomous pharmacy.
Omnicell (NASDAQ:OMCL) reported a strong second quarter for 2021, with total revenues of $272.7 million, up 36.6% from the previous year. GAAP net income surged to $20.4 million ($0.43 per diluted share), compared to a net loss in Q2 2020. Non-GAAP net income also rose significantly to $44.1 million ($0.97 per diluted share). The company expects Q3 2021 revenues between $281 million and $286 million and projects total 2021 revenues to range from $1.100 billion to $1.115 billion, reflecting strong demand and plans for acquisitions.
Omnicell (NASDAQ:OMCL) has announced a definitive agreement to acquire FDS Amplicare for $177 million. This acquisition aims to enhance Omnicell's EnlivenHealth division by integrating a suite of financial management, analytics, and population health solutions. The deal is anticipated to broaden Omnicell’s service offerings, allowing pharmacies to improve patient outcomes and expand clinical services. The acquisition, subject to regulatory approvals, is expected to close in the second half of 2021 and will be immediately accretive to Omnicell's non-GAAP earnings.
Omnicell has expanded its Board of Directors from 9 to 10 members with the appointment of Edward P. Bousa as an independent director. Mr. Bousa, a former executive at Wellington Management Company, brings nearly 40 years of asset management experience, including significant expertise in healthcare investments. His addition is part of Omnicell's strategy to refresh its board, enhancing its governance capabilities with a focus on improving health outcomes and operational efficiencies in medication management. The board now features 8 independent directors.
Omnicell, Inc. (Nasdaq: OMCL) is set to release its financial results for Q2 2021 before the market opens on July 29, 2021. A conference call to discuss these results will follow at 8:30 a.m. ET. The company's solutions aim to enhance medication management across healthcare systems, utilized by over 7,000 facilities globally. Omnicell focuses on improving patient outcomes and reducing costs through automation and analytics, benefiting over 50,000 pharmacies in North America and the UK. Investors can access the call via phone or the company’s investor relations website.
Omnicell has partnered with Chartwell Pennsylvania to implement its IVX Workflow sterile compounding technology for managing chemotherapy drug preparations. This collaboration aims to enhance safety and accuracy in medication management, utilizing gravimetric verification and barcode scanning. The system facilitates direct orders from clinical pharmacists to cleanrooms and is set for expansion to all home infusion therapies. This partnership underscores Omnicell's commitment to improving clinical outcomes and operational efficiency in pharmacy care delivery.
Omnicell, Inc. (Nasdaq: OMCL) has secured a multi-year agreement with Scripps Health to enhance pharmacy supply chain management across its San Diego network. The partnership includes the implementation of Omnicell's XT Automated Dispensing Systems and the cloud-based intelligence service, Omnicell One™. These technologies aim to improve medication management workflows, control costs, and reduce waste. Omnicell's solutions reflect a commitment to transforming the pharmacy care delivery model, positioning the company as a leader in the Autonomous Pharmacy movement.
Omnicell, a leader in medication management solutions, reported first quarter 2021 revenues of $251.8 million, a 9.6% increase year-over-year. GAAP net income was $14.1 million, or $0.30 per diluted share, up from $11.3 million in Q1 2020. Non-GAAP net income rose to $37.5 million, or $0.83 per diluted share. The company projects Q2 2021 revenues between $265 million and $270 million.
For the full year, total revenues are expected between $1.085 billion and $1.105 billion.
Omnicell, Inc. (Nasdaq: OMCL) announced a partnership between its EnlivenHealth™ division and Twilio to enhance patient engagement solutions for retail pharmacies. This collaboration aims to integrate Twilio's cloud communication technology, optimizing workflows while maintaining personal interactions. EnlivenHealth's solutions, deployed in over 30,000 pharmacies, will now include advanced features like personalized communications, SMS, and mobile apps. This partnership is part of Omnicell's vision to advance the Autonomous Pharmacy Model, improving patient outcomes and business performance for health providers.